Whiting USA Trust II EV/EBIT
Was ist das EV/EBIT von Whiting USA Trust II?
EV/EBIT von Whiting USA Trust II ist 0.32
Was ist die Definition von EV/EBIT?
Enterprise value to earnings before interest and taxes (EV/EBIT) is a financial ratio used to measure if a stock is priced appropriately to similar stocks and the market. It is similar to the P/E ratio.
ttm (trailing twelve months)
The EV/EBIT ratio addresses some of the shortcomings of the P/E ratio. Instead of taking market capitalization, the ratio uses enterprise value, as it takes into account the true value of the company. Enterprise value includes both equity and debt. It is calculated as:
Enterprise value = market cap + total debt – cash and cash equivalents
The EV/EBIT ratio is useful in comparing peers within the wider market. A high EV/EBIT ratio indicates that a company’s stock is overvalued. On the opposite, a low EV/EBIT ratio indicates that a company’s stock is undervalued. The lower the ratio, the more financially stable a company should be. However, investors and analyst should use other ratios and information to get a full picture of a company’s financial state and actual value.
EV/EBIT von Unternehmen in Energy Sektor auf OTC im Vergleich zu Whiting USA Trust II
Was macht Whiting USA Trust II?
Whiting USA Trust II holds a term net profits interest in the oil and gas producing properties located in the Permian Basin, Rocky Mountains, Gulf Coast, and Mid-Continent regions of the United States. Its oil and gas properties include interests in approximately 364.1 net producing oil and natural gas wells located in 42 predominately mature fields with established production profiles in 8 states. The company was founded in 2011 and is based in Houston, Texas. Whiting USA Trust II is a subsidiary of Whiting Petroleum Corporation.
Unternehmen mit ev/ebit ähnlich Whiting USA Trust II
- Oncternal Therapeutics hat EV/EBIT von 0.28
- Sulliden Mining Capital hat EV/EBIT von 0.29
- J4 Ventures hat EV/EBIT von 0.29
- Sulliden Mining Capital hat EV/EBIT von 0.30
- Bio-Path Inc hat EV/EBIT von 0.31
- Freeline Therapeutics plc hat EV/EBIT von 0.31
- Whiting USA Trust II hat EV/EBIT von 0.32
- Valencia Capital hat EV/EBIT von 0.33
- BlueCity hat EV/EBIT von 0.33
- Aclaris Therapeutics Inc hat EV/EBIT von 0.35
- Zafgen hat EV/EBIT von 0.35
- Xenetic Biosciences Inc hat EV/EBIT von 0.35
- Ocwen hat EV/EBIT von 0.35